- Conditions
- Amblyopia
- Interventions
- Luminopia, Eye Patch
- Device · Other
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 4 Years to 7 Years
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 58 more
Location Directory
Clinical trials in Philadelphia, Pennsylvania
This page shows live ClinicalTrials.gov search results for Philadelphia, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
17099
Shown on this page
12
Current sort
Recently updated
Location scope
Philadelphia, PA
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 61–72 of 17,099 matching trials in Philadelphia, PA.
Live ClinicalTrials.gov results.
Institutions in Philadelphia
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Sarcoma Metastatic
- Interventions
- ICG INFUSION 5MG/KG
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Phildelphia, Pennsylvania
- Conditions
- Juvenile Myoclonic Epilepsy
- Interventions
- JZP926 capsule, Placebo
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 20 more
- Conditions
- Fabry Disease
- Interventions
- Lucerastat
- Drug
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Irvine, California • Oakland, California + 10 more
- Conditions
- Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
- Interventions
- VE303, Placebo
- Biological
- Lead sponsor
- Vedanta Biosciences, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 852 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 84
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Quemliclustat, Placebo, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 41 more
- Conditions
- Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System Diseases, Brain Cancer
- Interventions
- silevertinib in combination with temozolomide, temozolomide (TMZ)
- Drug
- Lead sponsor
- Black Diamond Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Springdale, Arkansas • La Jolla, California + 33 more
- Conditions
- Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Medulloblastoma
- Interventions
- Fimepinostat, Therapeutic Conventional Surgery
- Drug · Procedure
- Lead sponsor
- Sabine Mueller, MD, PhD
- Other
- Eligibility
- 3 Years to 39 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 18
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 15 more
- Conditions
- Primary Generalized Tonic-Clonic Seizures
- Interventions
- XEN1101, Placebo
- Drug
- Lead sponsor
- Xenon Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 62
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
- Interventions
- Semaglutide, Placebo (Semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 54
- States / cities
- Fairhope, Alabama • Mobile, Alabama • Beverly Hills, California + 47 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Obinutuzumab, Questionnaire Administration, Venetoclax
- Procedure · Biological · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 625
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 443 more
- Conditions
- Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
- Interventions
- Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin, Computed Tomography, Cyclophosphamide, Dacarbazine, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Fludeoxyglucose F-18, Involved-site Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Prednisolone, Prednisone, Procarbazine Hydrochloride, Questionnaire Administration, Vinblastine Sulfate, Vincristine Sulfate
- Procedure · Biological · Drug + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 5 Years to 60 Years
- Enrollment
- 1,875 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 404
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 298 more